Ended Q1 with approximately $42.9M in cash, cash equivalents and short-term investments, which excludes the $50.0M in gross proceeds received in the recently completed private placement. “We are pleased with the significant progress made so far this year in the development of tegoprubart for use both in kidney transplantation and in the emerging fields of xenotransplantation and islet cell transplantation. This progress reinforces tegoprubart’s potential to become the first-line immunosuppressive treatment option of choice for a broad range of transplant procedures,” said CEO David-Alexandre Gros.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELDN:
- Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
- Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress
- Eledon Pharmaceuticals price target raised to $16 from $13 at H.C. Wainwright
- Eledon Pharmaceuticals Secures $50M Through Private Placement
- Eledon Pharmaceuticals to sell 13.1M shares at $2.37 in private placement